Expression and immunogenicity assessment of a plant-made immunogen targeting the cytotoxic T-lymphocyte associated antigen-4: a possible approach for cancer immunotherapy
Article
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
Cancer immunotherapy is a promising intervention to fight against this global health problem. In particular targeting immune checkpoints, such as cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed-death protein 1 (PD-1), by specific monoclonal antibodies is a current treatment for many malignances. A possible innovation in this field is based on the induction of humoral responses in the host by suppressing the effects of such immune checkpoints and as consequence favoring the activation of cellular immunity against the tumor cells. In this study, chimeric protein comprising the B subunit of Escherichia coli heat-labile enterotoxin as carrier and the extracellular domain of CTLA-4 (LTB-CTLA4) was produced in Nicotiana benthamiana by transient expression. The recombinant protein was accumulated up to 1.29 μg/g of leaves fresh weight on 4 day-post-infiltration. The integrity of the plant-made LTB-CTLA4 antigen was confirmed by western blot analysis and ELISA. Immunogenicity of the plant-made LTB-CTLA4 was assessed in BALB/c mice and the results showed that humoral responses were induced against both the LTB and CTLA-4 moieties. The plant–made LTB-CTLA4 stands as a promising candidate for the design of advanced protection studies against cancer in murine models. © 2021 Elsevier B.V.
publication date
funding provided via
published in
Research
keywords
cancer immunotherapy; CTLA-4; LTB; plant-made vaccine; recombinant protein Antigens; Diseases; Electrophoresis; Escherichia coli; Mammals; Monoclonal antibodies; Recombinant proteins; T-cells; Cancer immunotherapy; Current treatments; Cytotoxic T lymphocytes; Extracellular domains; Heat-labile enterotoxin; Nicotiana benthamiana; Transient expression; Western-blot analysis; Plants (botany); cancer vaccine; CD3 antigen; chimeric protein; cytotoxic T lymphocyte antigen 4; cytotoxic T lymphocyte antigen 4 antibody; cytotoxic T lymphocyte antigen 4 peptide; escherichia coli heat labile enterotoxin subunit b cytotoxic T lymphocyte antigen 4; Escherichia enterotoxin; ganglioside GM1; immune checkpoint inhibitor; immunoglobulin G; immunoglobulin G antibody; immunoglobulin G1; peptide derivative; recombinant protein; restriction endonuclease; saci protein; signal peptide; unclassified drug; xbai protein; bacterial toxin; cytotoxic T lymphocyte antigen 4; Escherichia coli protein; animal experiment; animal model; antibody response; antibody titer; antigenicity; Article; cancer immunotherapy; controlled study; enzyme linked immunosorbent assay; Escherichia coli; expression vector; female; flow cytometry; fresh weight; human; human cell; humoral immunity; male; mouse; Nicotiana benthamiana; nonhuman; plant leaf; priority journal; protein analysis; protein expression; protein purification; tumor immunogenicity; Western blotting; animal; Bagg albino mouse; cytotoxic T lymphocyte; immunotherapy; neoplasm; Animals; Bacterial Toxins; CTLA-4 Antigen; Escherichia coli Proteins; Immunotherapy; Mice; Mice, Inbred BALB C; Neoplasms; T-Lymphocytes, Cytotoxic
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue